Clinical Application of Population Pharmacokinetics in Pediatric Patients

Population pharmacokinetics (PopPK) plays a crucial role in optimizing drug dosing in pediatric patients, who exhibit significant variability in drug absorption, distribution, metabolism, and elimination compared to adults. This review highlights the clinical applications of PopPK modeling in pediatrics, emphasizing its utility in improving drug safety and efficacy in children. By considering demographic factors, such as age, weight, and maturation, as well as disease-specific characteristics, PopPK models enable the development of age-appropriate dosing regimens for a wide range of medications. The application of PopPK has been particularly beneficial in pediatric oncology, infectious diseases, and chronic conditions where drug dosing must be tailored to ensure therapeutic efficacy while minimizing adverse effects. We discuss the advantages of using PopPK models in predicting drug concentration-time profiles and optimizing therapeutic drug monitoring (TDM) in pediatric patients. Furthermore, we explore the integration of genetic and clinical data into PopPK models to refine dosing strategies, thereby addressing the unique pharmacokinetic challenges faced by children. Despite the promising benefits, challenges such as limited pediatric-specific data, ethical concerns in clinical trials, and the need for model validation remain. Ultimately, PopPK represents an important step toward personalized pediatric pharmacotherapy, ensuring better clinical outcomes and reduced risks for young patients.